Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy

M.P.W. has received consultancy or speaking fees from Biogen, Novartis, Roche, Celgene, IXICO, Sanofi Genzyme, Bayer Healthcare, Biologix, Genilac and Merck Serono. C.E.T. has served on advisory boards for Roche, has received nonfinancial support in the form of research consumables from ADx NeuroSciences and Euroimmun, and has performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen Prevention Center, Boehringer, Axon Neuroscience, EIP Pharma, PeopleBio, and Roche. B.M.J.U. reports personal fees from Genzyme, Biogen Idec, Teva Pharmaceutical Industries, Merck Serono, and Roche. J.K. has accepted speaker and consulting fees from Merck Serono, Biogen, Roche, Teva Pharmaceutical Industries, Genzyme, and Novartis. The other authors report no disclosures.